Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preliminary Results

14 May 2012 07:10

RNS Number : 2301D
Sterling Green Group PLC
14 May 2012
 



14 May 2012

 

STERLING GREEN GROUP PLC

 

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2012

 

CHAIRMAN'S STATEMENT

 

Introduction

I am pleased to present the financial statements of Sterling Green Group plc ("the Company") covering the year ended 31 March 2012.

 

Results and dividends

The loss after taxation for the year amounted to £516,000 (2011 - £1,902,000). The loss includes costs and losses amounting to £344,000 in respect of the disposal of the Company's principal trading subsidiaries in December 2011. Ongoing administrative expenses remained relatively unchanged compared to the previous financial year.

 

Proposed acquisition

Following the fundamental change of the trading business of the Company in December 2011, the Directors have been seeking to acquire another company or business in exchange for the issue of ordinary shares.

 

I am pleased to report that full details of such a proposed acquisition are being announced today and an AIM Admission Document containing full details of the proposals has been posted to shareholders today. Under the AIM Rules the proposed acquisition will constitute a reverse takeover due to the current size of acquisition relative to the current size of the Company. The Company is also proposing to raise £10,000,000 before expenses through a conditional placing of 90,909,091 new ordinary shares at a placing price of 11 pence per share (following its share consolidation described below) to provide working capital for the enlarged group. It is also proposed that the Company will effect a re-organisation of its existing share capital whereby each holding of 38 existing ordinary shares will be consolidated into one new ordinary share.

 

The AIM Admission Document contains a notice of General Meeting, which contains resolutions seeking shareholders' approval of the proposals. Should shareholders approve the proposed acquisition, placing and related matters, the enlarged group will be focussed on developing projects and opportunities in the oil and gas sector.

 

Notice of Annual General Meeting and posting of accounts

The Company announces that its 2012 Annual Report and Accounts for the year ended 31 March 2012, together with a Notice of the Annual General Meeting have been posted to shareholders and are now available to download from the Company's website at http://sterlinggreen.co.uk/sgg/

 

The Company's forthcoming Annual General Meeting will be held at 10.00 a.m. on 8 June 2012 at the Number 14, The Embankment, Vale Road, Heaton Mersey, Stockport SK4 3GN.

 

 

J M Edelson

Chairman

14 May 2012

 

 

 

Contact Details:

 

Sterling Green Group plc Tel:

Michael Edelson

+44 (0) 845 217 8293

Shore Capital (Nominated Adviser & Broker)

Nomad

Bidhi Bhoma

Edward Mansfield

 

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

FTI Consulting

Billy Clegg

Edward Westropp

+44 (0) 207 831 3113

 

 

 

 

 

STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 MARCH 2012

 

 

 

Note

2012

£000

2011

£000

 

Administrative expenses

(172)

(175)

Loss from continuing operations

(172)

(175)

Loss from discontinued operations

5

(344)

(1,727)

 

Loss and total comprehensive income for the year attributable to equity holders of the parent

 

 

(516)

 

 

(1,902)

Loss per share - basic and diluted

7

From continuing operations

From discontinued operations

From continuing and discontinued operations

 

 

(0.06)

(0.11)

(0.17)

(0.06)

(0.57)

(0.63)

 

 

There were no other items of comprehensive income other than the loss for the year.

 

 

 

STATEMENT OF FINANCIAL POSITION

AS AT 31 MARCH 2012

 

Company number: 5316808

 

Note

2012

£000

2011

£000

Non-current assets

Investment in subsidiaries

8

-

700

Current assets

Trade and other receivables

10

287

4

Cash and cash equivalents

9

149

1

Total current assets

436

5

Current liabilities

Trade and other payables

11

(274)

(27)

Total current liabilities

(274)

(27)

Net current assets/(liabilities)

162

(22)

Net assets

162

678

Equity

Called up share capital

12

304

304

Share premium account

1,794

1,794

Capital reserve

6

6

Other reserve

-

891

Accumulated losses

(1,942)

(2,317)

 

Total equity

 

162

 

678

 

 

 

 

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 MARCH 2012

 

 

 

Note

 

2012

£000

 

2011

£000

Cash flows used in operating activities

Loss before tax

(516)

(1,902)

Adjustments for:

Impairment loss on liquidation of subsidiary

346

2,232

Impairment loss on disposal of subsidiaries

64

-

Investment income

(105)

(505)

Operating cash flows before movement in working capital

(211)

(175)

Increase in trade and other receivables

(283)

(1)

Increase/(Decrease) in trade and other payables

247

(2)

Net cash used in operating activities

(247)

(178)

Cash flows from investing activities

Loans repaid by subsidiaries

585

179

Loans to subsidiaries

(190)

-

Net cash from investing activities

395

179

Net increase in cash and cash equivalents

148

1

Cash and cash equivalents at the start of the year

1

-

Cash and cash equivalents at the end of the year

9

149

1

 

Net cash used in operating activities includes outflows of £39,000 (2011 - £ nil) and net cash from investing activities includes inflows of £395,000 (2011 - £179,000) that relate to discontinued operations.

 

 

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 MARCH 2012

 

Share

capital

 

 

£000

Share

premium

account

 

£000

Capital

reserve

 

 

£000

 

Other

reserve

 

 

£000

Accum-ulated

losses

 

£000

Total

 

 

 

£000

At 1 April 2010

304

1,794

6

891

(415)

2,580

Loss and total comprehensive income for the year

 

 

-

 

 

-

 

 

-

 

 

-

 

 

(1,902)

 

 

(1,902)

 

At 31 March 2011

 

304

 

1,794

 

6

 

891

 

(2,317)

 

678

Loss and total comprehensive income for the year

 

 

-

 

 

-

 

 

-

 

 

-

 

 

(516)

 

 

(516)

Reclassification

-

-

-

(891)

891

-

 

At 31 March 2012

 

304

 

1,794

 

6

 

-

 

(1,942)

 

162

 

Other reserve

The other reserve is a merger reserve created on the acquisition of Sterling Green Limited. Following the appointment on 3 February 2012 of a liquidator for Sterling Green Limited, the merger reserve has been reclassified at the balance sheet date to accumulated losses.

 

 

  

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2012

 

 

1. Accounting policies

Sterling Green Group plc is a company incorporated in the United Kingdom under the Companies Act 2006.

 

The principal accounting policies are summarised below. They have been consistently applied throughout the period covered by the financial statements.

 

Basis of preparation

The financial information set out in this announcement has been prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS.

The Directors have considered the Company's financial position and prospects using detailed forecasts covering the period ending 31 December 2013. These forecasts have been drawn up on the basis that the proposed reverse takeover is approved by shareholders at a General Meeting, whilst at the same time a proposed fundraising is completed at an estimated amount of £10,000,000 before costs. On this basis, and having made appropriate consideration, the Board believes that the Company has adequate resources to continue trading for the foreseeable future, and accordingly, the going concern basis has been adopted in preparing these financial statements as shareholder approval is considered likely to occur.

 

However, the Directors have also considered the Company's financial position on the basis that the proposed reverse takeover is not approved by shareholders and no further funds are raised. The Directors believe that, after taking account of professional fees relating to an unsuccessful transaction, the Company would not have sufficient funds available to enable it to continue as a going concern whilst remaining an AIM listed company. Accordingly, the Directors believe that the correct course of action would be to propose to shareholders that the Company be wound up.

 

This represents a material uncertainty related to events or conditions which may cast significant doubt on the Company's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business. However, subject to this uncertainty the Board believes that the Company has adequate resources to continue trading for the foreseeable future, and accordingly, the going concern basis has been adopted in preparing these financial statements.

 

Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements in conformity with IFRS requires management to make estimates and judgements that affect the reported amounts of assets and liabilities as well as the disclosure of contingent assets and liabilities at the year end and the reported amounts of revenues and expenses during the reporting period. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

 

The estimates and judgements that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

 

a) Key sources of estimation uncertainty

Investments and intergroup balances impairment

The carrying value of the company's investment in its subsidiaries, including all intergroup balances, is assessed for impairment at each year end.

 

Trade and other receivables

£285,000 of costs relating to the proposed reverse takeover have been deferred and will be reclassified as a cost of investment once the proposed reverse takeover has been approved. Should the proposed reverse takeover not be approved then these costs will be limited to £167,000 and expensed.

 

Trade and other payables

 Included in accruals is an amount of £249,000 in respect of the estimated costs of the proposed reverse takeover that had been incurred prior to the year end. Should the proposed reverse takeover not be approved by shareholders then these costs would be limited to £167,000.

 

b) Critical judgements in applying the Company's accounting policies

As the Company is a non-trading cash shell at the year end there have been no critical judgements made in the preparation of these financial statements.

 

New standards and interpretations

There were a number of standards and interpretations which were in issue at 31 March 2012 but were either not effective at 31 March 2012 or have not been applied in preparing these financial statements. The Directors have assessed the full impact of these accounting changes on the Company. To the extent that they may be applicable, the Directors have concluded that none of these pronouncements will cause material adjustments to the Company's financial statements.

 

Investments

Investments in subsidiary undertakings are stated at cost except where, in the opinion of the Directors, there has been a permanent diminution in the value of an investment, in which case an appropriate impairment adjustment is made. Cost includes those costs directly related to acquisitions. In the current year as the acquisition had not been completed, these costs have been carried forward in trade and other receivables and will be reclassified once shareholder approval of the transaction has been obtained.

 

Financial instruments

Financial instruments are classified on initial recognition as financial assets, financial liabilities or equity instruments in accordance with the substance of the contractual arrangement. Financial instruments are recognised on the balance sheet at fair value when the Company becomes party to the contractual provisions of the instrument. Financial assets are reduced by appropriate allowances for estimated irrecoverable amounts. Interest earned from financial assets and interest paid on financial liabilities is recognised in the income statement on an accruals basis over the term of the financial asset or liability using the effective rate of interest.

 

Trade and other receivables are stated at their nominal value, as the interest that would be recognised from discounting future cash receipts over the short credit period is not considered to be material.

 

Trade and other payables are stated at their original invoiced value, as the interest that would be recognised from discounting future cash payments over the short term payment period is not considered material.

 

Deferred taxation

Deferred tax is provided in full using the liability method. Deferred tax is the future tax consequences of temporary differences between the carrying amounts and tax bases of assets and liabilities shown on the balance sheet. Deferred tax assets and liabilities are not recognised if they arise in the following situations: the initial recognition of goodwill; or the initial recognition of assets and liabilities that affect neither accounting nor taxable profit. The amount of deferred tax provided is based on the expected manner of recovery or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantially enacted at the balance sheet date.

 

A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilised. The carrying amount of the deferred tax assets are reviewed at each balance sheet date and reduced

to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the asset to be recovered.

 

Cash and cash equivalents

Cash comprises cash on hand and bank balances. Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash, which are subject to an insignificant risk of changes in value and have a maturity of three months or less at the date of acquisition.

 

For the purposes of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

 

2. Publication of Non-Statutory Accounts

The financial information set out in this announcement does not constitute the Company's statutory financial statements for the year ended 31 March 2012 or 2011. The financial information for 2011 is derived from the statutory financial statements for 2011. Full audited accounts in respect of that financial period have been delivered to the Registrar of Companies. The statutory financial statements for 2012 will be delivered to the Registrar of Companies following the Company's Annual General Meeting. The auditor has reported on the 2012 and 2011 financial statements. The 2012 and 2011 financial statements did not contain a statement under the Companies Act 2006 s498(2) and both received an unqualified audit opinion. However there was an emphasis of matter in relation to going concern in both opinions.

 

 

3. Auditor's remuneration

2012

£000

2011

£000

Fees payable to the auditor for the audit of the annual financial statements

 

14

 

9

Fees payable to the auditor for other services: Taxation

Corporate finance

3

25

1

-

42

10

 

4. Staff costs and Directors' remuneration

Staff costs, which include the remuneration of the Directors, were as follows:

 

2012

£000

2011

£000

 

Salaries and fees

 

 

68

74

Social security costs

4

4

 

72

78

In addition to the Directors, the Company employed one member of staff during the current and preceding year.

 

Directors' remuneration

The remuneration of the Directors' during the year was as follows:

 

2012

Salary/fees

£000

2012

Compensation for loss of office

£000

2012 Benefits

£000

2012

Total

£000

2011

Total

£000

Short term benefits:

J.M. Edelson

21

-

-

21

25

S.T. Ali

-

-

-

-

-

J. McClean

-

-

-

-

-

I. Aspinall

21

-

1

22

17

P.E. Kanas

14

5

-

19

15

L.J. Avigdori

1

-

-

115
 

57

5

1

63

72

 

 

 

 

5. Discontinued operations

 

2012

£000

2011

£000

 

Investment income

105

505

Administrative expenses

(39)

-

Impairment loss on disposal of subsidiaries

(64)

-

Impairment loss on liquidation of subsidiary

(346)

(2,232)

Loss from discontinued operations

(344)

(1,727)

 

No revenue was generated from discontinued operations other than investment income being dividends received from subsidiaries. For the reasons explained in note 5 there is no related tax credit.

 

6. Income tax

 

2012

£000

2011

£000

 

Current year income tax

-

-

At 31 March 2012 the Company had approximately £466,000 of excess management expenses which, should the proposed reverse acquisition be approved by shareholders, cannot be utilised against any future profits in the Company.

 

The income tax for the year can be reconciled to the Statement of Comprehensive Income as follows:

2012

£000

2011

£000

 

Loss before tax

(516)

(1,902)

 

Tax at the income tax rate of 26% (2011 - 28%)

 

Effects of:

 

(134)

 

(533)

 

Expenses not deductible for tax purposes

144

625

Group income

-

20

Group relief surrender

-

(112)

Utilisation of tax losses

(10)

-

Current tax for the year

-

-

 

7. Loss per share - basic and diluted

The calculation of loss per share is based on the following:

 

2012

2011

Loss for the year

Loss for the year from continuing operations (£000)

 

(172)

 

(175)

Loss for the year from discontinued operations (£000)

 

(344)

 

(1,727)

Loss for the year from continuing and discontinued operations (£000)

 

(516)

 

(1,902)

 

Number of shares

Weighted average number of shares

 

 

303,675,390

 

 

303,675,390

 

Loss per share

Loss per share from continuing operations (pence)

 

 

 

(0.06)

 

 

 

(0.06)

Loss per share from discontinued operations (pence)

 

(0.11)

 

(0.57)

Loss per share from continuing and discontinued operations (pence)

 

(0.17)

 

(0.63)

 

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue assuming conversion of all dilutive potential ordinary shares. During the year the Company's potential ordinary shares consist of share options. Due to losses in the current and preceding year there are no dilutive ordinary shares.

 

 

8. Investments in subsidiaries

Cost of shares

£000

Loans

£000

Total

£000

Cost

At 1 April 2010

1,142

1,464

2,606

Additions in the year

-

326

326

At 31 March 2011

1,142

1,790

2,932

Additions in the year

-

295

295

Repayments in the year

-

(585)

(585)

On disposal

-

(64)

(64)

At 31 March 2012

1,142

1,436

2,578

Impairment

At 1 April 2010

-

-

-

Charge for the year

1,142

1,090

2,232

At 31 March 2011

1,142

1,090

2,232

Charge for the year

-

410

410

On disposal

-

(64)

(64)

At 31 March 2012

1,142

1,436

2,578

Carrying value

At 31 March 2010

1,142

1,464

2,606

At 31 March 2011

-

700

700

At 31 March 2012

-

-

-

 

a) Sterling Green Limited

The rate of interest charged on the loan to Sterling Green Limited during the year was 7.5% (2011 - 7.5%).

 

The Directors considered that the Company's investment in Sterling Green Limited was impaired at 31 March 2011 and accordingly an impairment provision was made amounting to £2,232,000 in the financial statements for the year ended 31 March 2011. Following the appointment of a liquidator for Sterling Green Limited on 3 February 2012 the entire outstanding amount has been provided for at the year end resulting in a further impairment provision of £346,000 being made in the financial statements for the year ended 31 March 2012.

 

b) Taxdebts Limited and Sterling Green (Mortgages) Limited

On 21 December 2011 Taxdebts Limited was sold for £105 and Sterling Green (Mortgages) Limited was sold for £100. As part of the conditions of the sale of these companies, the remaining debt book not disposed of by Sterling Green Limited on 1 December 2011 was sold to Taxdebts Limited for £10,000 and, in addition, Taxdebts Limited took over the responsibility for the employment of 12 members of Sterling Green Limited's staff. The disposal resulted in the write off of a loan from Sterling Green Group plc to Taxdebts Limited amounting to £64,000.

 

9. Cash and cash equivalents

2012

£000

2011

£000

 Cash at bank

149

1

 

 

10. Trade and other receivables

2012

£000

2011

£000

Amounts due within one year

Prepayments and accrued income

2

4

Cost of reverse takeover

285

-

287

4

 

The cost of the reverse takeover has been deferred and will be reclassified as a cost of investment once the reverse takeover has been approved by shareholders. Details of the uncertainty in this estimate are disclosed in note 1.

 

11. Trade and other payables

2012

£000

2011

£000

 

Trade payables

6

12

Social security and other taxes

2

2

Accruals and deferred income

266

13

274

27

Trade payables comprise amounts outstanding for ongoing administration overhead. The carrying amount of trade payables approximates to their fair value. All trade payables are paid within credit terms.

 

Accruals include an amount of £249,000 in respect of the estimated costs of the proposed reverse takeover incurred prior to the year end. Details of the uncertainty in this estimate are disclosed in note 1.

 

12. Share capital

2012

£000

2011

£000

Allotted, called up and fully paid

303,675,390 Ordinary Shares of 0.1p each

304

304

 

 

 

 

13. Financial risk management

The Company's limited operations expose it to some financial risks arising from its use of financial instruments, the most significant ones being liquidity risk, market risk and credit risk. The Board of Directors is responsible for the Company's risk management policies. The main policies for managing these risks are as follows:

 

Liquidity risk

Liquidity risk arises from the management of working capital.

 

The Directors have prepared forecasts for the enlarged group for the period ending 31 December 2013 assuming the approval of the proposed reverse takeover and they consider the Company has sufficient working capital to cover all budgeted commitments during that forecast period.

 

However, should approval not be obtained then, after paying the estimated costs of an unsuccessful transaction, the Directors believe that the correct course of action would be to propose to shareholders that the Company be wound up.

 

Market risk

Market risk arises from the use of interest bearing financial instruments and represents the risk that future cash flows of a financial instrument will fluctuate as a result of changes in interest rates.

 

Given the low levels of bank balances held by the Company, the Directors do not believe that there is a significant interest rate risk.

 

Credit risk

Credit risk is the risk that the counterparty will default on its contractual obligations resulting in financial loss. Credit risk arises from cash and cash equivalents and from exposure via loans to subsidiary companies.

 

For cash and cash equivalents, the Company only uses recognised banks with high credit ratings. All cash and cash equivalents at 31 March 2012 are held with the Company's bankers, Allied Irish Bank (GB).

 

At the balance sheet date the Company's maximum credit risk exposure was £149,000 (2011 - £1,000) represented by cash and cash equivalents.

 

Categories of Company financial instruments

 

2012

2011

£000

£000

Financial assets:

Cash and cash equivalents

149

1

Total financial assets

149

1

 

Financial liabilities:

Trade and other payables

(272)

(25)

Total financial liabilities

(272)

(25)

 

Net

 

(123)

 

(24)

 

All financial assets are categorised as loans and receivables and all financial liabilities are categorised as financial liabilities measured at amortised cost.

 

The amortised cost of all financial assets and liabilities shown above is considered to also be the fair value of the Company's assets and liabilities.

 

 

 

 

14. Capital management

The Company is not subject to any externally imposed capital requirements. Accordingly, the Directors' primary objective when managing capital is to provide future returns to shareholders, whilst ensuring the Company's ability to continue as a going concern.

 

15. Related Party transactions

Key management are those persons having authority and responsibility for planning, controlling and directing the activities of the Company. In the opinion of the Board, the Company's key management are the directors of Sterling Green Group plc. Information regarding their compensation is given in note 3 to the financial statements.

 

The services of J M Edelson were provided to the Company under a service agreement by London & City Credit Corporation Limited. Amounts charged to the Company during the year for his services amounted to £20,833 (2011 - £25,000). At 31 March 2012 £nil (2011 - £2,500) of this amount remained outstanding.

 

During the year the Company loaned Sterling Green Limited an additional £126,000. Sterling Green Limited repaid £585,000 of the total loan to the Company during the year (2011 - £179,000 repaid). The interest charge on the entire loan during the year amounted to £105,307 (2011 - £104,850).

 

On 21 December 2011 two wholly owned trading subsidiaries were also disposed of. Taxdebts Limited was sold for £105 and Sterling Green (Mortgages) Limited was sold for £100. S.T Ali continued to be a Director of both of these companies after the disposal whilst J McClean also became a consultant to Taxdebts Limited. As part of the conditions relating to the sale of these companies, the remaining debt book not disposed of by Sterling Green Limited on 1 December 2011 was sold to Taxdebts Limited for £10,000 and, in addition, Taxdebts Limited took over the responsibility for the employment of 12 members of Sterling Green Limited's staff. The disposal resulted in the write off of a loan from Sterling Green Group plc to Taxdebts Limited amounting to £64,000.

 

The interests of the Directors who held office at 31 March 2012 in the issued share capital of the Company at the beginning (or date of appointment if later) and at the end of the financial year were as follows:

 

Number of ordinary shares of 0.1p each

31 March 2012

1 April 2011

J. M. Edelson

35,050,390

35,050,390

I. Aspinall

12,250,000

12,250,000

 

The shares held by J. M. Edelson include 1,000,000 held by his wife, J. B. Edelson, 1,000,000 held as a trustee of the Morris Edelson Settlement, 1,750,000 held by Novabank Capital Limited and 3,800,390 held by London and City Credit Corporation Limited.

 

The shares held by I. Aspinall include 8,250,000 held non-beneficially as a trustee of The Blueberry Charitable Trust and 4,000,000 held non-beneficially by his wife, J.M. Aspinall as a trustee of The Cheshire Children's Charitable Trust.

 

Throughout the year J. M. Edelson held options over 5,000,000 ordinary shares of 0.1 pence each with an exercise price of 0.1 pence per share. These options are exercisable at any time up to 29 October 2016.

 

Throughout the year I. Aspinall held options over 625,000 ordinary shares of 0.1 pence each with an exercise price of 0.1 pence per share. These options are exercisable at par any time up to 29 October 2016.

 

There have been no changes in the Director's interest in shares or share options between 31 March 2012 and the date these financial statements were approved.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR EALSDFSXAEFF
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.